PRKN and Parkinson disease: The mitophagy receptor BNIP3L/Nix located in the outer mitochondrial membrane, is an emerging target to enhance mitophagy for the treatment of PD, as BNIP3L/Nix appears to compensate for the loss-of-function mutation of the PRKN/PARK2 and restores mitophagy.